Symptomatic HFrEF | Novartis Egypt

ACEi: angiotensin-converting enzyme inhibitor; CI: confidence interval; CV: cardiovascular; HF: heart failure; HFrEF: heart failure with reduced ejection fraction; HR: hazard ratio; LVEF: left ventricular ejection fraction; OR: odds ratio; KCCQ:Kansas City Cardiomyopathy Questionnaire
* Stronger Heart: In PROVE-HF, LVEF increased vs baseline from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).¹ Stronger Life: In PARADIGM-HF, as compared with an Enalapril, ENTRESTO® reduced the risk of hospitalization for heart failure by 21% (HR, 0.79; 95% CI, 0.71 to 0.89; P<0.001) and change in KCCQ clinical summary score at 8 months (between-group difference, 1.64 points; 95% CI, 0.63 to 2.65; P=0.001).²
† ENTRESTO® must not be administered until 36 hours after discontinuing ACEi therapy.³
‡ HR for HF hospitalization 0.79; 95% CI, 0.71 to 0.89; P<0.001²
§ HR for CV death 0.80; 95% CI, 0.71 to 0.89; P<0.001²
# ENTRESTO® was significantly associated with a 5-point or greater improvement in change score difference in combined physical and social activity mean score with adjustment for baseline score at 8-month follow-up (OR, 1.12; 95% CI, 1.00-1.24; P = .04).⁴

Meet our patients: 1- Symptomatic heart failure with reduced ejection fraction

S.A suffers from shortness of breath and fatigue when he performs regular activities, dressing himself, showering or having a bath, and walking 100 yd on level ground⁴.

S.A, 66 Years

The patient is complaining of Heart Failure symptoms

not a real patient

Adapted from ref.4

Symptomatic heart failure patients are at risk for hospitalization and death.⁵

ENTRESTO® is for symptomatic HFrEF patients

PARADIGM-HF

PROVE-HF

HFrEF= heart failure with reduced ejection fraction; LVEF left ventricular ejection fraction; CVD: cardio vascular disease.

References

Januzzi JL, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, Camacho A, Piña IL, Rocha RA, Shah AM, Williamson KM. Association of change in N-terminal pro–B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. Jama. 2019 Sep 17;322(11):1085-95.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine. 2014 Sep 11;371(11):993-1004.
Egyptian Drug Authority (EDA). Entresto Approved Leaflet. Approval Date: 07/06/2021.
Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, Swedberg K, Rouleau JL, Shi VC, Lefkowitz MP, Katova T. Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA cardiology. 2018 Jun 1;3(6):498-505.
Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M. Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Circulation. 2016 Jun 7;133(23):2254-62.
Lewis EF, Claggett BL, McMurray JJ, Packer M, Lefkowitz MP, Rouleau JL, Liu J, Shi VC, Zile MR, Desai AS, Solomon SD. Health-related quality of life outcomes in PARADIGM-HF. Circulation: Heart Failure. 2017 Aug;10(8):e003430.
Summary Of Product Characteristics (SMPC). Entresto. Available at: https://www.ema.europa.eu/en/documents/product-information/entresto-epar-product-information_en.pdf. Last accessed at: 17/06/2025.

Entresto® API

PDF

Approved by Egyptian Drug Authority: HF0068OA4787/102025. Invalidation date: 04/05/2027.

Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg